Strathprints logo
Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Bacteriophage therapy - cooked goose or Phoenix rising?

Mattey, M. and Spencer, J. (2008) Bacteriophage therapy - cooked goose or Phoenix rising? Current Opinion in Biotechnology, 19 (6). pp. 608-612. ISSN 0958-1669

[img] Microsoft Word
Phage_therapyjsfinaldraft_1_.doc - Draft Version

Download (71kB)

Abstract

Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

Item type: Article
ID code: 19355
Keywords: bacteriophage therapy, animal, human trials, Virology, Biomedical Engineering, Bioengineering, Biotechnology
Subjects: Science > Microbiology > Virology
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences > Bioscience
Depositing user: Strathprints Administrator
Date Deposited: 02 Jun 2010 10:26
Last modified: 05 Sep 2014 01:49
URI: http://strathprints.strath.ac.uk/id/eprint/19355

Actions (login required)

View Item View Item